Search results
FDA lays out donanemab concerns ahead of meeting, as Lilly vigorously defends safety
FierceBiotech· 2 days agoThe docs for Eli Lilly’s donanemab advisory committee meeting are in: the FDA has raised concerns...
FDA Rescinds Ban on Juul E-Cigarettes
US News & World Report· 1 day agoFood and Drug Administration announced Thursday. While the company's e-cigarettes are back under review, they have not been fully cleared for sale in this country, the FDA ...
FDA warns parents about Crecelac infant formula—what parents need to know about the recall
Motherly via Yahoo News· 4 days agod3sign/Getty/FDA The FDA has issued an alert warning parents to avoid buying formula from a Texas...
FDA rolls back Juul marketing ban, reopening possibility of authorization
WLTX-TV Columbia· 2 days agoThe marketing denial orders were effectively paused by the agency not long after they were issued,...
FDA reverses US marketing halt on Juul vaping products
BBC News· 2 days agoThe US has reversed its ban on products sold by Juul, one of the country's top e-cigarette...
FDA rolls back Juul marketing ban, reopening possibility of authorization
CBS News· 2 days agoThe marketing denial orders were effectively paused by the agency not long after they were issued,...
FDA reverses its ban on Juul vaping products
Scripps News via AOL· 2 days agoThe U.S. Food and Drug Administration has reversed its ban on JUUL products, potentially opening the door for the brand to get its e-cigarettes and vapes...
FDA rejects MDMA drug for PTSD
WDVM via Yahoo News· 3 days agoAn FDA panel has rejected a first-of-its kind proposal to use the psychedelic drug MDMA as a treatment for PTSD, which could have a major impact on those...
FDA Panel Rejects MDMA Drug for PTSD
Medscape· 4 days agoA US Food and Drug Administration (FDA) expert panel has found that the benefits of the psychedelic midomafetamine (MDMA) in combination with psychological intervention for ...
FDA Advises Covid-19 Vaccine Makers to Tackle JN.1 Variant
Morningstar· 23 hours agoBy Sabela Ojea The Food and Drug Administration has recommended that manufacturers of Covid-19 vaccines should focus on the JN.1 variant beginning in the fall of 2024. The FDA
